Literature DB >> 30373796

Spontaneous Mutational Frequency and FKS Mutation Rates Vary by Echinocandin Agent against Candida glabrata.

Ryan K Shields1,2, Ellen G Kline1, Kelley R Healey3, Milena Kordalewska3, David S Perlin3, M Hong Nguyen4,2, Cornelius J Clancy1,5,6.   

Abstract

Echinocandins are front-line agents for treatment of invasive candidiasis. There are no reported agent-specific differences in Candida mutational frequency of resistance or propensity to develop FKS mutations. The objective of this study was to measure spontaneous and FKS mutation rates among Candida glabrata strains. Twenty bloodstream isolates from patients with or without prior echinocandin exposure were included. Minimum inhibitory concentrations (MICs), minimum fungicidal concentrations (MFCs), and mutation prevention concentrations were higher for caspofungin than for anidulafungin (P < 0.0001) and micafungin (P < 0.0001). Mutational frequencies of resistance at 3× the baseline MIC were highest for caspofungin and lowest for micafungin. A total of 247 isolates were recovered at or above the MFC for caspofungin (n = 159), anidulafungin (n = 74), or micafungin (n = 14). Agent-specific MIC increases were noted for anidulafungin and caspofungin, but not micafungin. Thirty-three percent of isolates harbored hot spot mutations in FKS1 (n = 6) or FKS2 (n = 76). Mutations at the Ser629 (Fks1) or Ser663 (Fks2) loci were more common after selection with anidulafungin or micafungin than with caspofungin (P = 0.003). Four isolates demonstrated >4-fold increases in MICs without FKS hot spot mutations; three of these harbored Fks2 mutations upstream of hot spot 1. The final isolate was FKS1 and FKS2 wild-type, but the 50% inhibitory concentrations of caspofungin and micafungin were increased 2.7- and 8-fold, respectively. In conclusion, micafungin may be superior in vitro to the other agents in limiting the emergence of resistance among C. glabrata Caspofungin exposure may be most likely to promote resistance development. These data provide a foundation for future investigations of newly developed echinocandin agents.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Candida glabratazzm321990; FKS; anidulafungin; caspofungin; echinocandin; micafungin; mutational frequency

Mesh:

Substances:

Year:  2018        PMID: 30373796      PMCID: PMC6325211          DOI: 10.1128/AAC.01692-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

Review 1.  The mutant selection window and antimicrobial resistance.

Authors:  Karl Drlica
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

2.  Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Elia Gómez G de la Pedrosa; Rafael Cantón; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

3.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 4.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

5.  Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species.

Authors:  Emilia Cantón; Javier Pemán; Angel Viudes; Guillermo Quindós; Miguel Gobernado; Ana Espinel-Ingroff
Journal:  Diagn Microbiol Infect Dis       Date:  2003-03       Impact factor: 2.803

6.  The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Andrea L Kwa; Shaoji Cheng; Chen Du; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

7.  FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.

Authors:  Nicholas D Beyda; Julie John; Abdullah Kilic; Mohammad J Alam; Todd M Lasco; Kevin W Garey
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

8.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

9.  Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model.

Authors:  Yanan Zhao; Brendan Prideaux; Yoji Nagasaki; Min Hee Lee; Pei-Yu Chen; Landry Blanc; Hsinpin Ho; Cornelius J Clancy; Minh Hong Nguyen; Véronique Dartois; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

10.  Comparison of echinocandin antifungals.

Authors:  Gregory Eschenauer; Daryl D Depestel; Peggy L Carver
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

View more
  10 in total

1.  Identification of Candida glabrata Transcriptional Regulators That Govern Stress Resistance and Virulence.

Authors:  Elan E Filler; Yaoping Liu; Norma V Solis; Ling Wang; Luis F Diaz; John E Edwards; Scott G Filler; Michael R Yeaman
Journal:  Infect Immun       Date:  2021-02-16       Impact factor: 3.441

Review 2.  Candidiasis and Mechanisms of Antifungal Resistance.

Authors:  Somanon Bhattacharya; Sutthichai Sae-Tia; Bettina C Fries
Journal:  Antibiotics (Basel)       Date:  2020-06-09

Review 3.  Microevolution of the pathogenic yeasts Candida albicans and Candida glabrata during antifungal therapy and host infection.

Authors:  Pedro Pais; Mónica Galocha; Romeu Viana; Mafalda Cavalheiro; Diana Pereira; Miguel Cacho Teixeira
Journal:  Microb Cell       Date:  2019-02-08

Review 4.  Rezafungin-Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins.

Authors:  Guillermo Garcia-Effron
Journal:  J Fungi (Basel)       Date:  2020-11-01

5.  Emergence of resistant Candida glabrata in Germany.

Authors:  Alexander Maximilian Aldejohann; Michaela Herz; Ronny Martin; Grit Walther; Oliver Kurzai
Journal:  JAC Antimicrob Resist       Date:  2021-08-07

6.  Case Report: Echinocandin-Resistance Candida glabrata FKS Mutants From Patient Following Radical Cystoprostatectomy Due to Muscle-Invasive Bladder Cancer.

Authors:  Maria Szymankiewicz; Krzysztof Kamecki; Sylwia Jarzynka; Anna Koryszewska-Bagińska; Gabriela Olędzka; Tomasz Nowikiewicz
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

Review 7.  Inanimate Surfaces as a Source of Hospital Infections Caused by Fungi, Bacteria and Viruses with Particular Emphasis on SARS-CoV-2.

Authors:  Agata Jabłońska-Trypuć; Marcin Makuła; Maria Włodarczyk-Makuła; Elżbieta Wołejko; Urszula Wydro; Lluis Serra-Majem; Józefa Wiater
Journal:  Int J Environ Res Public Health       Date:  2022-07-01       Impact factor: 4.614

8.  Determinants of fluconazole resistance and echinocandin tolerance in C. parapsilosis isolates causing a large clonal candidemia outbreak among COVID-19 patients in a Brazilian ICU.

Authors:  Farnaz Daneshnia; João N de Almeida Júnior; Amir Arastehfar; Lisa Lombardi; Erika Shor; Lis Moreno; Ana Verena Mendes; Maria Goreth Barberino; Danilo Thomaz Yamamoto; Geraldine Butler; David S Perlin; Arnaldo Lopes Colombo
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

9.  Resistance to Echinocandins Complicates a Case of Candida albicans Bloodstream Infection: A Case Report.

Authors:  Laura Trovato; Dafne Bongiorno; Maddalena Calvo; Giuseppe Migliorisi; Albino Boraccino; Nicolò Musso; Salvatore Oliveri; Stefania Stefani; Guido Scalia
Journal:  J Fungi (Basel)       Date:  2021-05-21

10.  Candidiasis by Candida glabrata, Candida nivariensis and Candida bracarensis in Galleria mellonella: Virulence and Therapeutic Responses to Echinocandins.

Authors:  Ainara Hernando-Ortiz; Elena Eraso; Guillermo Quindós; Estibaliz Mateo
Journal:  J Fungi (Basel)       Date:  2021-11-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.